Beyond Meat Inc
Change company Symbol lookup
Select an option...
BYND Beyond Meat Inc
NDENF Central African Gold Inc
HD Home Depot Inc
ACPS AC Partners Inc
FONR Fonar Corp
WBRRFX BlackRock Russell 2000 Growth Index Fund
WSM Williams-Sonoma Inc
BLK BlackRock Inc
TSEM Tower Semiconductor Ltd
CG Carlyle Group Inc
Go

Consumer Staples : Food Products | Mid Cap Growth
Company profile

Beyond Meat, Inc. offers plant-based burgers. The Company offers its products in a range of categories, such as The Beyond Burger, Beyond Sausage, Beyond Beef Crumbles and Beyond Chicken Strips. The Company sells a range of plant-based products across the three main meat platforms of beef, pork and poultry. It provides Beyond Mushroom Bacon Cheeseburger, Chef Spike’s Original Brat, Roasted Garlic & Italian Sausage Pasta, Beyond Beef Tacos and April Ross’ Butternut Squash Mac-N-Cheese. The Company also offers Beyond Spring Burger, Beyond Nacho Burger, Beyond Sausage Stuffed Peppers, Tuscan Style Beyond Sausage Pasta, Beyond Brat Breakfast Burrito, Beyond Beef Fiesta Power Bowl, Beyond Beef Nachos, Truffle Mac & Cheese Beyond Burger, Love & Lemons Guacamole Beyond Burger and Beyond Burger Tostada With Marinated Kale.

Closing Price
$184.14
Day's Change
0.56 (0.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
188.59
Day's Low
181.10
Volume
(Light)
Volume:
2,255,048

10-day average volume:
3,944,401
2,255,048

Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid(TM) Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation

9:30 am ET September 9, 2020 (PR Newswire) Print

Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study (EFS) of the Intrepid(TM) Transcatheter Tricuspid Valve Replacement (TTVR) system in patients with severe, symptomatic tricuspid regurgitation, a disease in which the diseased, damaged or malfunctioning tricuspid valve allows blood to flow back into the heart's upper right chamber causing eventual heart failure or death. The study begins on the heels of a recent Breakthrough Device Designation issued by the FDA for the Intrepid TTVR System. The Intrepid TTVR system is an investigational device worldwide.

"We're beginning a new journey that we believe will open the door for the potential future treatment of patients with tricuspid valve regurgitation, who constitute a significant, patient population suffering from heart valve disease today," said Azeem Latib, M.D., section head of interventional cardiology and medical director of structural heart interventions at Montefiore Medical Center in New York City and co-principal investigator in the study. "There has been much progress regarding transcatheter replacement of diseased aortic valves, but whether we can replace the tricuspid valve without open heart surgery represents a new frontier in cardiology."

Representing a large, unmet clinical need, tricuspid regurgitation affects more than 2 million patients in the United States. It is a highly undertreated disease due to the morbidity and mortality associated with surgical intervention.

Medtronic recently received Breakthrough Device Designation by the FDA for the Intrepid TTVR system. The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

"The clinical experience generated during this initial study phase will be critical for the future of the therapy, as many of these patients are not good candidates for traditional surgical tricuspid valve interventions due to their poor right heart functions and are higher risk due to co-morbidities," said Vinayak (Vinnie) Bapat, M.D., chief of cardiothoracic surgery at the Minneapolis Heart Institute and co-principal investigator in the study. "We are optimistic that these early learnings will help fuel additional clinical research and device innovation around this treatable disease."

The Intrepid transcatheter valve is the same valve being evaluated for the treatment of symptomatic mitral valve regurgitation in the transfemoral mitral early feasibility study. The device is implanted using a transfemoral delivery catheter, which assists physicians in delivering and placing the valve through a catheter inserted in the femoral vein.

About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Joey Lomicky     Ryan Weispfenning
Public Relations Investor Relations
+1-763-381-1204  +1-763-505-4626

https://mma.prnewswire.com/media/1246632/Medtronic_Logo.jpg

https://c212.net/c/img/favicon.png?sn=CG15799&sd=2020-09-09

View original content to download multimedia:http://www.prnewswire.com/news-releases/medtronic-receives-breakthrough-device-designation-from-fda-begins-early-feasibility-study-for-investigational-intrepid-transcatheter-valve-system-for-the-treatment-of-tricuspid-valve-regurgitation-301124531.html

SOURCE Medtronic plc

https://rt.prnewswire.com/rt.gif?NewsItemId=CG15799&Transmission_Id=202009090930PR_NEWS_USPR_____CG15799&DateId=20200909

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.